Lastest from Businesswire
Upstart Publishes June 2026 Origination Volume
BURLINGAME, Calif.--(BUSINESS WIRE)--Upstart Publishes June 2026 Origination Volume
Walker & Dunlop Arranges $232 Million Financing for Workforce Housing Portfolio
BETHESDA, Md.--(BUSINESS WIRE)--Walker & Dunlop arranged $232,352,000 in financing for a portfolio of five multifamily properties totaling 1,585 units across Arkansas and Florida.
Skillsoft Completes Sale of Global Knowledge Business, Advancing Focus on AI-Native Skills Management Platform
BOSTON--(BUSINESS WIRE)--Skillsoft (NYSE: SKIL), a leading AI-native skills management platform, today announced that it has completed the sale of its Global Knowledge business to an affiliate of Enduring Ventures. With the transaction complete, Skillsoft has a simplified portfolio focused entirely on its AI-native skills management platform. As AI changes which skills matter and how quickly they evolve, Skillsoft helps organizations track that shift and act on it. Skillsoft expects to maintain
Unum Group Announces $3.8 Billion Long-Term Care Reinsurance Transaction with Fortitude Re
CHATTANOOGA, Tenn.--(BUSINESS WIRE)--Unum Group (NYSE: UNM) announced today that its Unum Life Insurance Company of America subsidiary (“Unum America”) has entered into an agreement to cede to Fortitude Reinsurance Company Ltd. (“Fortitude Re”), on a coinsurance basis, certain individual long-term care (“LTC”) insurance policies representing $3.8 billion of statutory reserves in Fairwind Insurance Company, a wholly owned subsidiary of Unum (“Fairwind”). At closing, Unum America will recapture t
Sofinnova Partners Announces Myricx Bio Agrees to Be Acquired by Novartis
PARIS & LONDON--(BUSINESS WIRE)--Sofinnova Partners, a leading European life sciences venture capital firm, today announced that its portfolio company Myricx Bio (“Myricx”) has reached agreement to be acquired by Novartis, for up to $1.5 billion including $1.1 billion cash upfront plus potential milestone payments. This marks Sofinnova Partners' seventh exit in three years. Myricx Bio is a UK-headquartered transatlantic biotech company focused on the discovery and development of a novel class o

